{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Avastin+and+Temozolomide", "query": { "intervention": "Avastin and Temozolomide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 71, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Avastin+and+Temozolomide&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T23:10:14.060Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01105702", "title": "Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Cancer" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Lithium Carbonate", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2010-05", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-08-04", "last_synced_at": "2026-09-29T23:10:14.060Z", "location_count": 2, "location_summary": "Summit, New Jersey • New York, New York", "locations": [ { "city": "Summit", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01105702" }, { "nct_id": "NCT00501891", "title": "Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Metronomic Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2007-07", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-09-29T23:10:14.060Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00501891" }, { "nct_id": "NCT03554707", "title": "SGT-53 in Children With Recurrent or Progressive CNS Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Childhood CNS Tumor" ], "interventions": [ { "name": "SGT-53", "type": "GENETIC" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "RADIATION", "DRUG" ], "sponsor": "SynerGene Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 0, "start_date": "2022-06-01", "completion_date": "2022-06-01", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-09-29T23:10:14.060Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03554707" }, { "nct_id": "NCT01182350", "title": "Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Karen D. Wright MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 53, "start_date": "2011-09", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-09-29T23:10:14.060Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01182350" }, { "nct_id": "NCT01525082", "title": "Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrinoma", "Glucagonoma", "Insulinoma", "Pancreatic Polypeptide Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Pancreatic Cancer", "Somatostatinoma", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Shaheen Shagufta", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2012-12", "completion_date": "2019-12-31", "has_results": true, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-09-29T23:10:14.060Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525082" }, { "nct_id": "NCT00811993", "title": "A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "RG1507", "type": "DRUG" }, { "name": "RO1507", "type": "DRUG" }, { "name": "bevacizumab [Avastin]", "type": "DRUG" }, { "name": "capecitabine [Xeloda]", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "erlotinib [Tarceva]", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "pemetrexel", "type": "DRUG" }, { "name": "sorafenib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "trastuzumab [Herceptin]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2009-02", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-29T23:10:14.060Z", "location_count": 8, "location_summary": "Tucson, Arizona • San Francisco, California • Santa Monica, California + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00811993" }, { "nct_id": "NCT03128047", "title": "HUMC 1612: Optune NovoTTF-200A System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High Grade Glioma", "Ependymoma" ], "interventions": [ { "name": "Optune NovoTTF-200A System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "5 Years to 21 Years" }, "enrollment_count": 7, "start_date": "2017-04-06", "completion_date": "2025-04-05", "has_results": true, "last_update_posted_date": "2025-07-08", "last_synced_at": "2026-09-29T23:10:14.060Z", "location_count": 2, "location_summary": "Orlando, Florida • Hackensack, New Jersey", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03128047" }, { "nct_id": "NCT01217437", "title": "Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Neoplasm", "Pineoblastoma", "Recurrent Medulloblastoma", "Recurrent Primitive Neuroectodermal Tumor", "Refractory Medulloblastoma", "Refractory Peripheral Primitive Neuroectodermal Tumor" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 108, "start_date": "2010-11-22", "completion_date": "2021-06-30", "has_results": true, "last_update_posted_date": "2021-07-23", "last_synced_at": "2026-09-29T23:10:14.060Z", "location_count": 136, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 103 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217437" }, { "nct_id": "NCT03149575", "title": "VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma Multiforme", "Glioblastoma", "Glioma", "GBM", "Brain Cancer" ], "interventions": [ { "name": "VAL-083, Dianhydrogalactitol", "type": "DRUG" }, { "name": "Physician's Choice of Salvage Therapy - temozolomide", "type": "DRUG" }, { "name": "Physician's Choice of Salvage Therapy - lomustine", "type": "DRUG" }, { "name": "Physician's Choice of Salvage Therapy - carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DelMar Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-10-27", "completion_date": "2019-08-31", "has_results": false, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-09-29T23:10:14.060Z", "location_count": 5, "location_summary": "Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Summit", "state": "New Jersey" }, { "city": "Amherst", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03149575" }, { "nct_id": "NCT01740258", "title": "Bevacizumab Beyond Progression (BBP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Glioma", "Grade 4 Malignant Glioma", "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2013-01", "completion_date": "2019-11-14", "has_results": true, "last_update_posted_date": "2021-01-26", "last_synced_at": "2026-09-29T23:10:14.060Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01740258" } ] }